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CASE REPORTA rare case of late-onset lichenoid photodermatitis
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Vandetanib (ZD6474, Zactima) is a novel inhibitor
of multiple tyrosine kinases that has been used for the
treatment of various malignancies including medul-
lary thyroid carcinoma.1 The drug functions primarily
via inhibitory effects on vascular endothelial growth
factor receptors, epidermal growth factor receptors,
and the RET-tyrosine kinase system.2 As with other
targeted chemotherapy agents, several cutaneous
side effects including folliculitis, palmar-plantar hy-
perkeratosis, desquamation, cutaneous hyperpig-
mentation, and photosensitization have been
reported.3,4 Photosensitivity, although less commonly
reported, was found to make up 37% of cutaneous
adverse effects in one case series.3 Most of these
patients were found to exhibit a sunburnlike ery-
thema in sun-exposed regions with subsequent
desquamation. However, a small subset of patients
exhibited a phenotypically lichenoid photodermatitis
and a lymphocytic interface dermatitis with basal
vacuolization and keratinocyte apoptosis upon his-
topathology. Only a handful of cases describing
similar lichenoid eruptions after vandetanib use
have been reported, most of which developed within
a few weeks after exposure.5-8 We present a patient
with a late-onset lichenoid photodermatitis that
began 5months after initiation of vandetanib therapy.CASE REPORT
A 61-year-old African-American man with
Fitzpatrick type IV skin was referred to our derma-
tology department with a 1-month history of painful
and severe sunburn. In 2002, he had medullary
thyroid cancer diagnosed and underwent total thy-
roidectomy with adjuvant radiation. Despite initialthe Department of Dermatology, Eastern Virginia Medical
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ease involving his lungs, liver, and bones. He subse-
quently was started on vandetanib therapy at 300 mg
daily in December 2012.
Approximately 5 months after initiation of vande-
tanib, a painful, erythematous eruption developed in
sun-exposed regions after gardening outdoors. In the
clinic, he had multiple vesicles, erosions, and scaly
pink papules over his sun-exposed face, chest, upper
back, and dorsal forearms (Fig 1, A-C). No additional
medications had been added to his regimen since
beginning vandetanib therapy, and his only treat-
ment was topical silver sulfadiazine; he denied taking
any other known photosensitizing medications. A
rheumatoid factor assay and erythrocyte sedimenta-
tion rate were both markedly elevated, but a com-
plete blood count, basic metabolic panel, and
antinuclear antibody test were all within normal
limits. The patient denied any myalgias or muscle
weakness. Skin biopsy specimens were taken from
representative areas.HISTOPATHOLOGY
Three specimens had similar histopathologic
findings that included orthohyperkeratosis, mild
hypergranulosis, mild spongiosis, basal vacuoliza-
tion, and scattered dyskeratotic cells. A bandlike
lymphoplasmacytic infiltrate was present in the
papillary dermis. Melanin granules were seen both
within macrophages and freely in the papillary
dermis (Fig 2).DISCUSSION
Our patient’s clinical and histologic findings are
supportive of a lichenoid photo-induced dermatitis.JAAD Case Reports 2015;1:141-3.
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Fig 1. A-C, Pink, lichenified, and faintly hyperpigmented papules and plaques with scale and
fine erosions overlying sun-exposed areas.
Fig 2. Specimen shows a bandlike lymphoplasmacytic
infiltrate with basal vacuolization, dyskeratosis, mild spon-
giosis, and orthohyperkeratosis. Pigment incontinence is
evident in the upper papillary dermis. (Hematoxylin-eosin
stain; original magnification: 310.)
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vandetanib has been described in a few case reports
and a small case series.3-8 One author hypothesized
that photodermatitis was related to deposition of
drug or drug metabolites within the dermis.6
However, the exact mechanism of vandetanib-
induced photosensitivity remains unclear. In vitro
studies have found that vandetanib has a low mo-
lecular weight and polycyclic structure similar to
other known photosensitizing agents and that van-
detanib may exert its photosensitizing effects
through induction of reactive oxygen species, DNA
cleavage, and cell apoptosis.9 It has also been shown
that vandetanib inhibits the ABCG2 transporter-
associated protein, which suggests a porphyrialike
mechanism.10 Although the cutaneous porphyrias,
such as porphyria cutanea tarda, can be associated
with a chronic lichenoid photodermatitis, there areno studies to our knowledge evaluating porphyrin
levels in patients taking vandetanib.
Given the findings from the aforementioned
in vitro studies, it would be reasonable to extra-
polate that phototoxicity plays a key role in the
pathogenesis of vandetanib-related photosensitivity.
However, phototoxicity typically develops within
hours to days. With regard to the spectrum of
cutaneous side effects of vandetanib, the most
commonly reported photosensitive eruptions mani-
fest within a few days to weeks as severe sunburns
with erythematous desquamation.3 The timeline for
these eruptions may be consistent with phototox-
icity; however, most of the previously described
photo-induced lichenoid eruptions exhibit a longer
time until onset of symptoms.
One case report by Fava et al7 describes a similar
photosensitive lichenoid eruption that occurred
3 months after initiation of therapy. The authors
hypothesized that this delayed case presentation was
indicative of photoallergy. In another case series, the
median time to development of an eruption was
8 weeks.3 Our patient did not display symptoms until
26 weeks after initiation, but the patient’s clinical and
histopathologic findings were remarkably similar to
the few previously described cases.
One potential source of confounding is that our
patient began vandetanib therapy in the wintertime.
The atmospheric ultraviolet light burden may not
have been sufficient to trigger photosensitivity at that
time; however, his symptoms did not begin until late
May—somewhat later than expected for seasonal
ultraviolet light variation. The use of silver sulfadia-
zine to affected areas may have caused additional
confounding. Although photosensitivity is not typi-
cally seen with silver sulfadiazine, it can be associ-
ated with an irritant dermatitis and localized argyria;
both of these adverse effects may obfuscate the
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silver sulfadiazine until after the onset of symptoms,
and although he achieved no benefit from treatment,
he did not report any worsening of his symptoms.
Lastly, our patient reports that he had been
gardening outdoors near the time of onset; this could
have exposed him to additional plant-based photo-
allergens; however, he reported he had been
gardening for years prior without incident. Photo
patch testingwas offered to help rule out plant-based
photoallergy, but the patient declined.
Ultimately, our patient’s clinical presentationmost
strongly implicates vandetanib as the causative
etiology. Given the variable latency in presentation
between our case and those previously described,
there may be a spectrum of action in vandetanib-
mediated photosensitivity, including acute-to-
subacute phototoxicity and a delayed cell-mediated
photoallergy. Accordingly, awareness of this
phenomenon must be maintained throughout
the duration of treatment with vandetanib,
and patients should be counseled appropriately
regarding sun-protective behaviors.
Because any type of photosensitivity can be
physically debilitating, the question of whether to
discontinue vandetanib therapy emerges. In one
previously documented case, cessation of vandeta-
nib therapy resulted in clearance of symptoms with
residual postinflammatory hyperpigmentation.6
Another case report describes transient clearance
after stopping vandetanib but resensitization with
subsequent docetaxel use.5 These 2 cases illustrate
the potential for improvement after discontinuation
of therapy; however, the latter case suggests that
vandetanib therapy may have permanent implica-
tions for future chemotherapy. Moreover, termina-
tion of therapy is not an option for many patients on
vandetanib, considering the high mortality associ-
ated with the underlying disease. Vandetanib may
represent a final treatment option. One patient who
remained on vandetanib for 3 years after an initial
eruption experienced attenuation of symptoms with
the use of sunscreen and sun avoidance.6 For our
patient, we opted for topical corticosteroids, oral
antihistamines, and sun avoidance for symptomatic
relief while making the decision to continue with
vandetanib therapy.The emergence of new kinase receptor inhibitors
and their cutaneous side effects presents a challenge
for dermatologists and dermatopathologists. Given
the increasing number of patients on this medication,
the profile of adverse effects associated with vande-
tanib is still evolving. Associated photosensitive erup-
tions are well reported in the literature. We propose
the need for heightened awareness regarding this late-
onset variant that may represent photoallergy. New
rashes developing many months into treatment with
vandetanib should be thoroughly assessed as a po-
tential side effect. Early discussion of sun protection
and sunscreen use at the onset of therapy is quintes-
sential for maximizing patient benefit and prevention.
Furthermore, treatment has the potential for complex
decision making, which inevitably will benefit from
multidisciplinary discussion.REFERENCES
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